298 related articles for article (PubMed ID: 17192166)
1. Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.
Klibanov OM; Clark-Vetri R
Pharmacotherapy; 2007 Jan; 27(1):122-36. PubMed ID: 17192166
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
Mounier N; Katlama C; Costagliola D; Chichmanian RM; Spano JP
Crit Rev Oncol Hematol; 2009 Oct; 72(1):10-20. PubMed ID: 19070506
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
4. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
5. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?
Clayton A; Mughal T
Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis against adverse effects of chemotherapy for HIV positive patients].
Bentata M
Bull Cancer; 2003 May; 90(5):427-34. PubMed ID: 12850766
[TBL] [Abstract][Full Text] [Related]
7. The oncology impact of highly active antiretroviral therapy.
Schlichemeyer R; Chambers C; Gill MJ
J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
[TBL] [Abstract][Full Text] [Related]
8. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
10. Advances in human immunodeficiency virus therapeutics.
Clay PG; Dong BJ; Sorensen SJ; Tseng A; Romanelli F; Antoniou T
Ann Pharmacother; 2006 Apr; 40(4):704-9. PubMed ID: 16551767
[TBL] [Abstract][Full Text] [Related]
11. HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre.
Kiely B; O'Flaherty J; Surah S; Kieran J; O'Donnell D; Bergin C; Mulcahy F
Int J STD AIDS; 2010 May; 21(5):332-6. PubMed ID: 20498102
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Kong HH; Myers SA
Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
[TBL] [Abstract][Full Text] [Related]
13. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A; Flanigan TP; Carter EJ
Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
[TBL] [Abstract][Full Text] [Related]
14. Critical care of HIV infected patients in the highly active antiretroviral therapy era.
Corona A; Raimondi F
Minerva Anestesiol; 2007 Dec; 73(12):635-45. PubMed ID: 18046294
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
[TBL] [Abstract][Full Text] [Related]
16. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
Sension MG
J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
[TBL] [Abstract][Full Text] [Related]
17. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
18. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Barbaro G; Barbarini G
Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
20. Current status and future issues in the treatment of HIV-1 infection.
Matsushita S
Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
